1971-12
Lindenbaum digoxin paper (NEJM 285:1344–1347, 9 December 1971). Four chemically equivalent tablets, seven-fold serum-concentration spread. Converted "same drug" from a chemistry question to a PK question. Every BE regulation cites this paper directly or indirectly.
1974
OTA Drug Bioequivalence report to Congress. Documented multiple marketed drug products and categories with bioavailability concerns; recommended statutory BE testing and a dedicated FDA office.
1975-01-07
FDA proposed rule on bioavailability and bioequivalence requirements (40 FR 1237, 7 January 1975) — precursor to the 1977 final rule.
1977-01-07
21 CFR Part 320 (FDA, final rule 7 January 1977; 42 FR 1648). Foundational US bioavailability/bioequivalence regulation: defined the terms, mandated in vivo testing for designated drug classes, set the framework that subsequent guidance would populate with statistical methods.
1984
Hatch-Waxman Act (Drug Price Competition & Patent Term Restoration). Created the ANDA, made BE the gatekeeper for generic approval. Transformed the generic industry from non-viable to economic engine.
1987
Schuirmann's TOST (two one-sided tests) published in J Pharmacokin Biopharm. The statistical engine for 80–125%; not regulation, but cited in every subsequent BE guidance globally.
1989
Generic drug scandal. Multiple US generic firms — including Bolar Pharmaceutical, Vitarine Pharmaceuticals, and Par Pharmaceutical, with subsequent investigation extending to other manufacturers — investigated for falsified bioequivalence data, FDA bribery, and reference-product substitution. Triggered the legislative response of 1992.
1991-12
CPMP first adopts BA/BE Note for Guidance. The original European Note for Guidance on the Investigation of Bioavailability and Bioequivalence was adopted by CPMP in December 1991, predating its later restructuring under reference CPMP/EWP/QWP/1401/98.
1992-05-13
Generic Drug Enforcement Act (US Public Law 102-282, 13 May 1992; 106 Stat. 149). Gave FDA debarment authority over individuals and firms convicted of generic-drug fraud (including bribery and submission of false data); statutory response to the 1989 scandal.
1990s
80–125% log-transformed 90% CI consolidates as global default. The Schuirmann TOST framework, originally proposed 1987, becomes the de-facto international acceptance criterion through cumulative regulatory adoption rather than a single amendment.
1999-02-10
Lei 9.787 (Brazil) created the medicamento genérico legal category. RDC 391/1999 — ANVISA's first BE rule, modelled on 21 CFR 320 but with Brazilian reference-product designation.
2000-08
BCS biowaiver concept — FDA Guidance for Industry: Waiver of In Vivo BA/BE Studies for IR Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System (August 2000), operationalising Amidon 1995. Initially Class I only; Class III biowaivers came across regulators progressively, with ICH M9 (2019) harmonising Class I and III at the international level.
2001-07-26
EMA CPMP/EWP/QWP/1401/98 — revised Note for Guidance on the Investigation of Bioavailability and Bioequivalence, adopted by CPMP 26 July 2001 (legal effective date 1 January 2002). Replaced the original 1991 NfG; the 80–125% acceptance interval established as the EU standard.
late-2000s
Reference-scaled average bioequivalence (RSABE) develops within FDA's Office of Generic Drugs as the methodology for highly variable drugs. Reflected across multiple papers and product-specific guidances (progesterone, warfarin, others). EMA's framework for HV drugs adopts a related but distinct approach (Cmax widening only, not AUC).
2010
EMA Guideline on Investigation of Bioequivalence (CPMP/EWP/QWP/1401/98 Rev 1, effective August 2010). EMA framework matures; permits widening of acceptance for HV drugs on Cmax only (not AUC) — the major FDA-EMA divergence that persists.
2010s
FDA narrows acceptance limits for NTI drugs through product-specific guidances (warfarin among them) and the 2013 final guidance Bioequivalence Studies with Pharmacokinetic Endpoints for Drugs Submitted Under an ANDA. Tightened bounds (e.g. 90.00–111.11%) and full replicate design for designated NTI drugs; the precise first appearance of the 90.00–111.11% bound is in product-specific guidances rather than the general guidance.
2015
WHO TRS 992 Annex 7. Multisource (Generic) Pharmaceutical Products: Guidelines on Registration Requirements to Establish Interchangeability. Canonical multisource interchangeability framework for LMIC regulators; foundation for the WHO Prequalification Programme.
2017
WHO TRS 1003 Annex 6. Updated Multisource (Generic) Pharmaceutical Products: Guidelines on Registration Requirements to Establish Interchangeability. Replaced TRS 992 Annex 7 as the current canonical WHO multisource interchangeability framework.
2019-11-20
ICH M9 Step 4 — BCS-Based Biowaivers. Harmonised BCS Class I and Class III biowaiver criteria across ICH regions. Pivotal convergence event since the 80–125% bound.
2022
ANVISA RDC 742/2022. Brazilian regulation modernising bioequivalence requirements for generic and similar drugs. Specific provisions, predecessor RDCs revoked, and any explicit alignment to ICH M9 should be cited from the Diário Oficial da União text.
2024-07-23
ICH M13A Step 4 — Bioequivalence for Immediate-Release Solid Oral Dosage Forms (adopted by ICH Assembly 23 July 2024). The harmonisation document for BE study design itself: sample size, fasting / fed conditions, replicate vs crossover, statistical analysis. Region-by-region Step 5 implementation underway; ICH M13B (additional strengths biowaivers) and M13C concept papers and work plans in development — current Step status to be cited from ICH workplan.